BlogHealth

India’s first nasal vaccine by Bharat Biotech gets drug panel’s nod for ‘restricted use’

The Central Medicine Customary Management Organisation has authorised the vaccine for major immunisation in opposition to COVID-19 within the above 18 age group for ‘restricted use in an emergency scenario’

Representational picture. PTI

Related Articles

New Delhi: A nasal vaccine in opposition to COVID-19, developed by Covaxin-maker Bharat Biotech has been authorised for “restricted use” by India’s prime drug controller, Union well being minister Mansukh Mandaviya mentioned on Tuesday.

The Central Medicine Customary Management Organisation has authorised the vaccine for major immunisation in opposition to COVID-19 within the above 18 age group for “restricted use in an emergency scenario.”

The union well being minister additionally mentioned that India has harnessed its science, R&D, and human sources within the battle in opposition to COVID-19 underneath PM Narendra Modi’s management.

In response to a News18 report, in August, Bharat Biotech Worldwide Restricted (BBIL) mentioned that its COVID-19 intranasal vaccine (BBV154) has confirmed to be secure, well-tolerated, and immunogenic in topics in managed phase-3 medical trials.

The trials had been performed with the assistance of almost 4,000 volunteers, the report added.

With inputs from businesses

Learn all of the Newest Information, Trending InformationCricket Information, Bollywood Information,
India Information and Leisure Information right here. Comply with us on Fb, Twitter and Instagram.

Related Articles

Back to top button
close